ZimVie Inc. (Nasdaq: ZIMV), a leading global life sciences and dental technology company, announced its first quarter 2025 financial results, showing improved profitability and operating performance despite a slight revenue decline.
The company reported first quarter net sales of $112 million, down 5.2% from the same period last year, but also a significant reduction in net losses of $2.6 million, down $8.9 million from the first quarter of 2024.
Adjusted net income increased to $7.4 million, up from $2.2 million in the same period last year, and adjusted earnings per share (EPS) reached $0.27. Adjusted EBITDA also increased significantly, climbing to $17.6 million, representing 15.7% of net sales, an increase of 520 basis points year-over-year.
CEO Vafa Jamali emphasized the company’s continued focus on operational efficiency and innovation in dental care.
Looking ahead, ZimVie reaffirmed its full-year 2025 guidance, forecasting net sales between $445 million and $460 million, adjusted EBITDA of $65 million to $70 million, and adjusted EPS between $0.80 and $0.95.
Related topics:
